Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

Abstract Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are standard-of-care second-line therapies for relapsed or refractory large B-cell lymphomas, yet clinical and immunological predictors of durable benefit remain poorly defined. Here, we retrospectively analyze 64 pat...

Full description

Bibliographic Details

Main Authors:	Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael R. Cook, Nasheed M. Hossain, Colin J. Thomas, Vrutti Patel, Vitor B. de Souza, Mohannad H. Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Antonio Imparato, Alberto Carturan, Patrizia Porazzi, Joseph A. Fraietta, Stephen J. Schuster, Ivan Maillard, Marco Ruella, Daniel J. Landsburg
Format:	Artigo
Language:	Inglês
Published:	Nature Portfolio 2026-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-026-71710-7
Tags:	Add Tag No Tags, Be the first to tag this record!